Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients

BACKGROUND:: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD and polymorphisms of its gene are related to...

Full description

Bibliographic Details
Published in:Therapeutic Drug Monitoring
Main Author: Teh L.K.; Hamzah S.; Hashim H.; Bannur Z.; Zakaria Z.A.; Hasbullani Z.; Shia J.K.S.; Fijeraid H.; Md Nor A.; Zailani M.; Ramasamy P.; Ngow H.; Sood S.; Salleh M.Z.
Format: Article
Language:English
Published: 2013
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885023351&doi=10.1097%2fFTD.0b013e318290acd2&partnerID=40&md5=ba55042f4bf5b85b4800c13ea9480b73

Similar Items